Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together?
Saved in:
| Title: | Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together? |
|---|---|
| Authors: | Ambery P; Clinical Late Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Greasley PJ; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Menzies RI; Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Brynne L; Information Practice Late Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Kulkarni S; Department of Clinical Pharmacology and Therapeutics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB20QQ, U.K.; Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke's Hospital, Cambridge, U.K., Oscarsson J; Clinical Late Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Davenport AP; Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke's Hospital, Cambridge, U.K. |
| Source: | Clinical science (London, England : 1979) [Clin Sci (Lond)] 2024 Jun 05; Vol. 138 (11), pp. 687-697. |
| Publication Type: | Journal Article; Review; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Portland Press on behalf of the Medical Research Society and the Biochemical Society Country of Publication: England NLM ID: 7905731 Publication Model: Print Cited Medium: Internet ISSN: 1470-8736 (Electronic) Linking ISSN: 01435221 NLM ISO Abbreviation: Clin Sci (Lond) Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38835256 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together? – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Ambery+P%22">Ambery P</searchLink>; Clinical Late Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Greasley+PJ%22">Greasley PJ</searchLink>; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Menzies+RI%22">Menzies RI</searchLink>; Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Brynne+L%22">Brynne L</searchLink>; Information Practice Late Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Kulkarni+S%22">Kulkarni S</searchLink>; Department of Clinical Pharmacology and Therapeutics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB20QQ, U.K.; Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke's Hospital, Cambridge, U.K.<br /><searchLink fieldCode="AU" term="%22Oscarsson+J%22">Oscarsson J</searchLink>; Clinical Late Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Davenport+AP%22">Davenport AP</searchLink>; Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke's Hospital, Cambridge, U.K. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%227905731%22">Clinical science (London, England : 1979)</searchLink> [Clin Sci (Lond)] 2024 Jun 05; Vol. 138 (11), pp. 687-697. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Review; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Portland+Press+on+behalf+of+the+Medical+Research+Society+and+the+Biochemical+Society%22">Portland Press on behalf of the Medical Research Society and the Biochemical Society </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>7905731 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1470-8736 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201435221%22">01435221 </searchLink><i>NLM ISO Abbreviation: </i>Clin Sci (Lond) <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38835256 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1042/CS20240605 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 687 Titles: – TitleFull: Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together? Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Ambery P – PersonEntity: Name: NameFull: Greasley PJ – PersonEntity: Name: NameFull: Menzies RI – PersonEntity: Name: NameFull: Brynne L – PersonEntity: Name: NameFull: Kulkarni S – PersonEntity: Name: NameFull: Oscarsson J – PersonEntity: Name: NameFull: Davenport AP IsPartOfRelationships: – BibEntity: Dates: – D: 05 M: 06 Text: 2024 Jun 05 Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 1470-8736 Numbering: – Type: volume Value: 138 – Type: issue Value: 11 Titles: – TitleFull: Clinical science (London, England : 1979) Type: main |
| ResultId | 1 |
